Topic
Antitussive Agent
About: Antitussive Agent is a research topic. Over the lifetime, 380 publications have been published within this topic receiving 5776 citations.
Papers published on a yearly basis
Papers
More filters
Patent•
02 Aug 2018
TL;DR: In this paper, a composition containing Panax ginseng, Adenophora triphylla, Wolfiporia extensa, Rehmannia glutinosa, and Mel for an antitussive, expectorant, or anti-inflammatory action, and a composition for preventing, alleviating, or treating a respiratory disease.
Abstract: The present invention provides a composition containing, as active ingredients, Panax ginseng, Adenophora triphylla, Wolfiporia extensa, Rehmannia glutinosa, and Mel for an antitussive, expectorant, or anti-inflammatory action, and a composition for preventing, alleviating, or treating a respiratory disease. The present invention provides a compositions having excellent effects compared with an existing antitussive agent and expectorant agent. The compositions of the present invention are a naturally derived material and has little cytotoxicity, and thus is expected to be safely used as a medicine or food composition having antitussive, expectorant, and anti-inflammatory effects.
Patent•
19 Jul 1996TL;DR: Aryldecahydroisoquinoline compounds have been shown to have an excellent preventive effect on ischemic brain nerve cell necrosis, the effect of inhibiting the progression of cerebral infraction, a potent analgetic effect and an antitussive effect as mentioned in this paper.
Abstract: 4a-Aryldecahydroisoquinoline compounds typified by the compound of formula (1) or pharmacologically acceptable acid-addition salts thereof. When pharmacologically evaluated in vitro and in vivo, these compounds exhibit an excellent preventive effect on ischemic brain nerve cell necrosis, the effect of inhibiting the progression of cerebral infraction, a potent analgetic effect and an antitussive effect. Thus they are usable in the field of medicines as a brain cell protective agent to be used in order to prevent or treat cerebrovascular disorders, ischemic cerebral disorders, brain nerve cell disorders, dementia, etc., an analgetic agent and an antitussive agent.
01 Jan 2020
TL;DR: In this chapter the main antitussive drugs are examined, but for the sake of completeness, it is also discussed some other drugs often used to treat cough, though some of them are not commonly classified as antitussives agents.
Abstract: A wide range of disease processes may present with cough and definitive treatment depends on identifying the cause. Specific treatment of the cause should control the cough, but this may not occur in all cases, and in a sizeable proportion of patients, no associated cause can be found. In the settings of acute cough, symptomatic treatment is often the first line of therapy. Symptomatic treatment must be also considered when the cough interferes with the patient’s daily activities; however most of antitussive preparations have not been shown to be more effective than placebo in adequately performed clinical trials. In this chapter the main antitussive drugs are examined, but for the sake of completeness, it is also discussed some other drugs often used to treat cough, though some of them are not commonly classified as antitussive agents. Finally, it is reported recent therapeutic approach to refractory cough represented by the combination of behavioural therapy and the neuromodulator drugs.
Patent•
11 Oct 2018
TL;DR: In this paper, a method of treating cough, including acute cough, sub-acute cough and chronic cough, in a mammal in need thereof which comprises the administration of a therapeutically effective amount of a selected TRPV4 antagonist to such mammal.
Abstract: Invented is a method of treating cough; including acute cough, sub-acute cough and chronic cough, in a mammal in need thereof which comprises the administration of a therapeutically effective amount of a selected TRPV4 antagonist to such mammal.
Patent•
27 Jun 2003
TL;DR: In this article, an antitussive agent consisting of Cynanchi atratiradix extract (A) and carrier or excipient was used for preparation of (A).
Abstract: An antitussive agent comprises Cynanchi atratiradix extract (A) and carrier or excipient. An independent claim is included for preparation of (A). ACTIVITY : Antitussive. Pulverized dry material of Cynanchum atraturm (1 kg) was heated to boil and refluxed twice With 10 L of the following solvents: water (test-1), 50% ethanol (test-2), 95% ethanol (test-3), ethyl acetate (EA) (test-4) and hexane (test-5), respectively. The extracts were then filtered with 350 mesh sieve and the filtrates were collected, respectively. The filtrates were further centrifuged continuously at 1089xg ( Avanti J-251(RTM, High performance centrifuge)) for 3 hr to precipitate micropartic1es and impurities. The supernatants were further concentrated and freeze-dried. The inhibition activity of extracts (1 g/kg dosage) on citric acid induced cough was evaluated. The antitussive inhibition assessment showed at least 60% of citric acid-induced coughs. MECHANISM OF ACTION : None given.